HRTX logo

Heron Therapeutics, Inc.

HRTX

HRTX: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

more

Show HRTX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of HRTX by members of U.S. Congress

Politician Type Traded
Ashley Hinson Arenholz House / R Sale $1,001 - $15,000 Mar. 31, 2021
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by HRTX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $50,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $50,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $50,000 Oct 28, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Oct 20, 2021 Issue: Health Issues Medicare/Medicaid
  • $50,000 Jul 14, 2021 Issue: Health Issues Medicare/Medicaid
  • $50,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
  • $50,000 Jan 19, 2021 Issue: Medicare/Medicaid Health Issues
  • $50,000 Oct 19, 2020 Issue: Medicare/Medicaid Health Issues
  • $50,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2020 Issue: Medicare/Medicaid Health Issues
  • $50,000 Jan 22, 2020 Issue: Pharmacy Health Issues Medicare/Medicaid
  • $50,000 Oct 18, 2019 Issue: Medicare/Medicaid Health Issues
  • $50,000 Jul 18, 2019 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 17, 2019 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 15, 2019 Issue: None
  • $50,000 Jan 16, 2019 Issue: Pharmacy Medicare/Medicaid Health Issues
  • $50,000 Jan 15, 2019 Issue: Medicare/Medicaid
  • $50,000 Oct 18, 2018 Issue: Pharmacy Health Issues Medicare/Medicaid
  • $50,000 Oct 18, 2018 Issue: Medicare/Medicaid
  • $50,000 Jul 19, 2018 Issue: Health Issues Pharmacy Medicare/Medicaid
  • $50,000 Jul 19, 2018 Issue: Medicare/Medicaid
  • $40,000 Apr 18, 2018 Issue: Health Issues Medicare/Medicaid Pharmacy
  • $40,000 Jan 11, 2018 Issue: Medicare/Medicaid Health Issues Pharmacy
  • $40,000 Nov 20, 2017 Issue: Pharmacy
  • $40,000 Nov 20, 2017 Issue: Pharmacy
  • $40,000 Oct 19, 2017 Issue: Health Issues Medicare/Medicaid Pharmacy
  • $30,000 Jan 23, 2017 Issue: Pharmacy
  • $15,000 Jan 18, 2017 Issue: Health Issues
  • $30,000 Oct 20, 2016 Issue: Pharmacy
  • $15,000 Oct 19, 2016 Issue: Health Issues
  • $30,000 Jul 20, 2016 Issue: Pharmacy
  • $15,000 Jul 20, 2016 Issue: Health Issues
  • $30,000 Apr 20, 2016 Issue: Pharmacy
  • $15,000 Apr 19, 2016 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Long-acting polymeric delivery systems Aug. 16, 2022
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Feb. 22, 2022
  • Patent Title: Emulsion formulations of an nk-1 receptor antagonist and uses thereof Nov. 16, 2021
  • Patent Title: Long-acting polymeric delivery systems Aug. 10, 2021
  • Patent Title: Long-acting polymeric delivery systems Aug. 10, 2021
  • Patent Title: Compositions of a polyorthoester and an organic acid excipient Apr. 20, 2021
  • Patent Title: Emulsion formulations of aprepitant Mar. 23, 2021
  • Patent Title: Long-acting polymeric delivery systems Jan. 26, 2021
  • Patent Title: Emulsion formulations of aprepitant Dec. 10, 2019
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Sep. 03, 2019
  • Patent Title: Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Jul. 23, 2019
  • Patent Title: Long-acting polymeric delivery systems Feb. 26, 2019
  • Patent Title: Long-acting polymeric delivery systems Oct. 16, 2018
  • Patent Title: Emulsion formulations of aprepitant May. 22, 2018
  • Patent Title: Emulsion formulations of aprepitant May. 22, 2018
  • Patent Title: Emulsion formulations of an nk-1 receptor antagonist and uses thereof May. 22, 2018
  • Patent Title: Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron Mar. 13, 2018
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Mar. 13, 2018
  • Patent Title: Emulsion formulations of aprepitant Nov. 07, 2017
  • Patent Title: Long-acting polymeric delivery systems Oct. 31, 2017
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Aug. 29, 2017
  • Patent Title: Long-acting polymeric delivery systems Jul. 04, 2017
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Mar. 14, 2017
  • Patent Title: Emulsion formulations of aprepitant Feb. 07, 2017
  • Patent Title: Compositions of a polyorthoester and an aprotic solvent Sep. 20, 2016
  • Patent Title: Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron May. 06, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of HRTX in WallStreetBets Daily Discussion

HRTX News

Recent insights relating to HRTX

CNBC Recommendations

Recent picks made for HRTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in HRTX

Corporate Flights

Flights by private jets registered to HRTX